American Journal of Ophthalmology
Volume 149, Issue 3 , Pages 465-471.e1 , March 2010

One-Year Results of Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

,Accepted 30 September 2009.

References 

  1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials –TAP report 1. Arch Ophthalmol. 1999;117:1329–1345
  2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials –TAP report 2. Arch Ophthalmol. 2001;119:198–207
  3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes –TAP report No. 3. Arch Ophthalmol. 2002;120:1443–1454
  4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration : three-year results of an open-label extension of 2 randomized clinical trials –TAP report No. 5. Arch Ophthalmol. 2002;120:1307–1314
  5. Japanese Age-related Macular Degeneration Trial (JAT) Study Group. One-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;136:1049–1061
  6. Tano Y. Ophthalmic PDT Study Group: Guidelines for PDT in Japan. Ophthalmology. 2008;115:585585.e6
  7. Yannuzzi LA, Wong DW, Sforzolini BS, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117:1503–1510
  8. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133:639–648
  9. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392–1396
  10. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830–841
  11. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835–844
  12. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:2147–2154
  13. The Visudyne in Minimally Classic CNV (VIM) study group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol. 2005;123:448–457
  14. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci. 2006;47:371–376
  15. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography-guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2007;144:7–14
  16. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141–146
  17. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576–1584
  18. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:70–73
  19. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44:2147–2154
  20. Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748–757
  21. Sacu S, Varga A, Michels S, et al. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. Br J Ophthalmol. 2008;92:1347–1351
  22. Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2007;51:270–277
  23. Kurashige Y, Otani A, Sasahara M, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2008;146:513–519

PII: S0002-9394(09)00733-8

doi: 10.1016/j.ajo.2009.09.020

American Journal of Ophthalmology
Volume 149, Issue 3 , Pages 465-471.e1 , March 2010

Article Tools

* Image Usage & Resolution